COMMUNIQUÉS West-GlobeNewswire

Aardvark Therapeutics Announces Establishment of New U.S. Subsidiary to Support Development of Its Dermatology Pipeline; Bryan Jones Named Chief Executive Officer
12/02/2026
SAN DIEGO, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate [...]
PsiThera to Participate in Piper Sandler Virtual Novel Targets in Immunology Symposium
12/02/2026
WATERTOWN, Mass., Feb. 12, 2026 (GLOBE NEWSWIRE) -- PsiThera, Inc. today announced that Chief Executive Officer Eric Shaff, Founder and Chief Innovation Officer Woody Sherman, Ph.D., and Chief Scientific Officer Camil [...]
Vericel to Report Fourth-Quarter and Full-Year 2025 Financial Results on February 26, 2026
12/02/2026
CAMBRIDGE, Mass., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will report [...]
ImmuneSensor Therapeutics Doses First Patient with Aicardi Goutières Syndrome (AGS) in Phase 1b Clinical Study of cGAS inhibitor, IMSB301
12/02/2026
Trial expansion into AGS and other Type 1 interferonopathies follows successful Phase 1a clinical trial of IMSB301 in healthy volunteers, which demonstrated a well-tolerated safety profile and dose-dependent exposure [...]
Pacira Highlights New NOPAIN Act Survey Data Conducted by Voices for Non-Opioid Choices
12/02/2026
BRISBANE, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies, today highlighted new survey findings [...]
Annovis Secures DSMB Approval to Advance Pivotal Phase 3 Trial of Buntanetap in Alzheimer’s Disease
12/02/2026
MALVERN, Pa., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for [...]
NMDP Appoints Ginna Laport, MD, to New Senior Physician Leadership Role
12/02/2026
Dr. Laport brings 30 years of multi-disciplinary experience across academia, national leadership positions, and industry to advance clinical practice of NMDP cell therapy research MINNEAPOLIS, Feb. 12, 2026 (GLOBE [...]
Microbot Medical®’s LIBERTY® Endovascular Robotic System Highlighted at a Leading Vascular Disease Management Conference
12/02/2026
International Symposium on Endovascular Therapy (ISET) Convened Key Opinion Leaders to Discuss Advancements and Future Role of Endovascular Robotics LIBERTY ® Continues to Gain Commercial Traction and Exposure as Part [...]
Grace Therapeutics Announces Third Quarter 2026 Financial Results, Provides Business Update
12/02/2026
FDA Established April 23, 2026 as PDUFA Target Date for Review of Submission Seeking Approval for GTx-104 in the Treatment of Patients with aneurysmal Subarachnoid Hemorrhage (aSAH) Phase 3 STRIVE-ON Safety Trial Data [...]
Collegium to Report Fourth Quarter and Full-Year 2025 Financial Results on February 26, 2026
12/02/2026
STOUGHTON, Mass., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that it will report fourth quarter and full-year 2025 financial results before the market opens on [...]
Alira Health Earns EcoVadis Silver Rating, Ranking in the Top 15 Percent Globally
12/02/2026
Recognition underscores the company’s mission-driven approach to sustainability, ethics, and responsible growth FRAMINGHAM, Mass., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Alira Health today announced it has been awarded a [...]
Totus Medicines to Present Updated Phase 1 Clinical Data for TOS-358 at ESMO Targeted Anticancer Therapies Congress 2026
12/02/2026
Oral presentation to highlight updated Phase 1 monotherapy safety and efficacy data for TOS-358, a covalent PI3K a inhibitor Data will include efficacy and safety in heavily pretreated patients with PI3K a -mutant [...]
Trethera to Highlight Clinical Momentum and Indication Expansion at Biocom Global Partnering & Investor Conference
12/02/2026
LOS ANGELES, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company developing first-in-class therapies for cancer and autoimmune diseases, announces an upcoming [...]
Picard Medical/ SynCardia Highlights Successful Bridge-to-Transplant Case at UCSF Health Using the SynCardia Total Artificial Heart
12/02/2026
- Successful heart transplant case following an implanted SynCardia total artificial heart reported at hospital with one of the largest heart transplant programs in the country - TUCSON, Ariz., Feb. 12, 2026 (GLOBE [...]
Aprea Therapeutics Strengthens Global Patent Portfolio in DNA Damage Response (DDR) Cancer Therapeutics, Paving Way for Pipeline Growth
12/02/2026
New patents granted in 2025 in Australia and Japan bolster global IP coverage for Aprea’s WEE1 and ATR programs. Core patent families are expected to provide exclusivity into 2045. Lead WEE1 inhibitor candidate APR-1051 [...]
Emergent BioSolutions to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
12/02/2026
GAITHERSBURG, Md., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, February 26, 2026, at 5:00 pm eastern time to discuss the financial results for the [...]
Athelas Home Expands AI Diagnostics to the Point of Care with FDA Clearance
12/02/2026
MOUNTAIN VIEW, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Athelas, a Commure company, today announced that the FDA cleared the CLIA-waived Athelas Home diagnostic device for use in point-of-care settings. The AI-powered [...]
Cannara organisera une webdiffusion destinée aux investisseurs le 19 février 2026
12/02/2026
MONTRÉAL, 12 févr. 2026 (GLOBE NEWSWIRE) -- Cannara Biotech Inc. (« Cannara », la « Société », « nous » ou « notre ») ( TSXV : LOVE ) ( OTCQX : LOVFF ) ( FRA : 8CB0 ), producteur verticalement intégré de cannabis de [...]
Cronos Group Inc. to Hold 2025 Fourth Quarter and Full-Year Earnings Conference Call on February 26, 2026
12/02/2026
TORONTO, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos” or the “Company”) will hold its 2025 fourth quarter and full-year earnings conference call on Thursday, February 26, 2026 [...]

Pages